Universal CAR-T therapy takes on advanced colorectal cancer
NCT ID NCT06653010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side effects, while also seeing if tumors shrink. The study is currently on hold.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
Shenzhen Nanshan People's Hospital
Shenzhen, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?